This announcement is a separate document:
百奥泰 自愿披露关于BAT8006联合贝伐珠单抗获得药物临床试验批准通知书的公告
Biotech voluntarily disclosed the notice of approval for clinical trials of BAT8006 combined with bevacizumab
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.